Immune cell therapy takes on rare blood disorder
Disease control
Not yet recruiting
This early-phase trial tests a new treatment using a patient's own immune cells, engineered to target and destroy faulty immune cells that attack red blood cells. It is for people with a severe, hard-to-treat form of autoimmune hemolytic anemia. The study will check if the therap…
Phase: PHASE1, PHASE2 • Sponsor: Yihao Wang • Aim: Disease control
Last updated May 18, 2026 12:03 UTC